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Abstract
Objective—Fibromyalgia (FM) represents a complex disorder characterized by widespread pain
and tenderness and frequently accompanied by additional somatic and cognitive/affective
symptoms. Genetic risk factors are known to contribute to the etiology of the syndrome, but few
specific genetic variants have been identified to date and still require replication. In this study, a
large scale candidate gene approach was used to examine over 350 genes for association with FM.
Methods—Four hundred ninety-six FM patients were included in the study as cases with a total
of 348 chronic pain-free controls. Genotyping was performed using a dedicated gene array chip,
the Pain Research Panel, which assays variants characterizing over 350 genes known to be
involved in biological pathways relevant to nociception, inflammation, and mood. Association
testing was performed using logistic regression.
Results—Significant differences in allele frequencies between cases and controls were observed
for three genes: GABRB3 (rs4906902, p = 3.65×10−6), TAAR1 (rs8192619, p = 1.11×10−5) and
GBP1 (rs7911, p = 1.06×10−4). These three genes, and seven other genes with suggestive
evidence for association, were examined in a second, independent cohort of FM patients and
controls genotyped using the Perlegen 600K platform. Evidence of association in the replication
cohort was observed for TAAR1, RGS4, CNR1, and GRIA4 genes.
Conclusion—Variation in these genes may serve as a basis for development of new diagnostic
approaches, and these genes’ products may contribute to the pathophysiology of FM and represent
potential targets for therapeutic action.
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Fibromyalgia (FM) is a syndrome characterized by chronic widespread musculoskeletal pain
and joint tenderness. Other complaints and symptoms, such as affective distress,
hyperalgesia and allodynia, cognitive disturbance, and gastrointestinal disruption frequently
accompany the pain, and the diagnosis of FM is often comorbid with other functional
syndromes such as irritable bowel syndrome (IBS), temporomandibular joint disease
(TMJD), migraine, and vulvar vestibulitis (1, 2). Despite numerous hypotheses, as of yet no
single causative pathway has been discovered to explain the etiology of the syndrome. FM is
currently considered a complex disorder, with interplay between sensory abnormalities,
central nervous system dysfunction, psychological factors, and environmental triggers (1).
Evidence for familial aggregation (3) indicates genetic risk factors contribute to the etiology
of FM. Two recent twin studies of chronic widespread pain have estimated the heritability of
chronic pain symptoms at 48–54% (4) and 51% (5). Identifying the genes responsible for
this substantial genetic contribution to risk should provide a better understanding of the
complex mechanisms underlying FM and other chronic pain diseases.
A number of researchers have employed a candidate gene approach to search for FM-
associated genes. The majority of such candidates have been genes involved in
catecholaminergic or serotonergic neurotransmission, including receptors and transporters
for dopamine, serotonin, norepinephrine, and epinephrine, as well as the catabolic enzymes
COMT and MAO. Inconsistent results with these candidate genes have led others to
investigate nociceptive pathways potentially involved in chronic pain or affective symptoms,
including NOS, cytokines, opioids, and glucocorticoids. To date, no large scale candidate
gene panel or genome-wide association studies have been reported for an FM cohort.
The present study was undertaken as a more comprehensive approach to identifying genetic
markers that are associated with FM, using a two-step discovery and replication design. We
first employed a dedicated candidate gene platform, the Pain Research Panel, to look for
associations between FM and single nucleotide polymorphisms (SNPs) representing over
350 genes. Almost all of the genes previously investigated in FM have been included on the
Pain Research Panel, allowing us to confirm association findings from these studies. A large
number of additional genes related to nociception, inflammation, and mood are also assayed
by the Panel, providing a means to discover novel mechanisms that have not yet been
explored. Several gene loci initially associated in the discovery cohort were then examined
in a second sample of FM patients, genotyped using a commercial genome-wide association




Cases were 496 FM patients (study protocols Pfizer A0081056 [n=402] and A2571003
[n=94]) taken from two randomized, controlled clinical trials of analgesic compounds. All
subjects were Caucasian females at least 18 years of age that met ACR criteria for FM
(widespread pain present for >3 months, and tenderness in at least 11 of 18 tender point
sites). Subjects had no other inflammatory, rheumatic, or otherwise painful disease beside
FM, and were free of severe depression.
A pool of FM-free control subjects was derived from two sources. One hundred sixty-five
healthy controls were taken from a cohort designed as a reference population of psychiatric
and neurological normal volunteers (Pfizer GEN-0583 protocol), and included only
Caucasian females over 18 years of age with no history of chronic pain or depression. An
additional control cohort included pain-free subjects (n=224) from a case-control study of
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TMJD at the University of North Carolina at Chapel Hill (UNC, recruited under NIH grant
R01-DE16558 as described previously (6)). The 183 Caucasian female subjects from UNC
(not including 41 non-Caucasians that were included for purposes of racial clustering),
ranging in age from 18–45, were merged with the GEN subjects as a single control group.
All genotyped subjects voluntarily gave a blood sample (9 mL volume, collected in plastic
EDTA tubes) and written informed consent for anonymized genetic analysis. Study
protocols for all Pfizer and UNC cohorts were approved by their respective Institutional
Review Boards/Independent Ethical Committees to be in accordance with the Declaration of
Helsinki.
Genotyping
DNA extracted from whole blood was genotyped by Cogenics Inc. (Morrisville, NC, now
Beckman-Coulter Genomics) using the Algynomics Pain Research Panel. This platform is a
dedicated array for the targeted assessment of genes involved in acute and chronic pain
conditions, utilizing the Affymetrix MegAllele platform. The panel genotypes 3295 single
nucleotide polymorphisms (SNPs) corresponding to over 350 genes that represent three
overlapping domains: (i) genes that mediate the transmission of pain signals by sensory
nerve fibers and by CNS neural pathways that mediate the perception of pain; (ii) genes that
mediate peripheral and central inflammatory responses to tissue injury or psychological
stress; (iii) genes that influence mood and affective states associated with chronic pain
conditions.
Genotyping results were returned for 517 FM cases (A0081056 n=415, A2571003 n=102)
and 411 control subjects (GEN-0583 n=187, UNC n=224). Genotyping calls were checked
for quality and filtered using utilities implemented in PLINK version 1.04 (7). Samples were
removed from analysis due to non-Caucasian ancestry (n=38 in the Pfizer cohorts,
Supplemental Fig. 1), and a high degree of genetic similarity indicating duplicated samples
or cryptic relatedness (n=15). Samples were also removed after applying a filter for overall
genotype call rate <95% (n=31). SNPs were filtered based on call rate >95% (n=176); minor
allele frequency >1% in either case or control group (n=292); and agreement across 107
repeated samples >99% (n=27).
As the GEN and UNC control groups were genotyped in separate batches 6 months apart,
missingness rates were compared before combining them, as a test for SNPs most sensitive
to technical bias. SNPs were also checked for agreement with Hardy-Weinberg equilibrium,
in cases and controls separately.
The final cleaned dataset included 2760 SNPs in 496 FM cases and 348 controls, with an
average call rate of 99.8%. The data cleaning steps are summarized in the Supplementary
Materials (Table 1).
Replication cohort
A replication study was used to confirm suggestive results from the primary analysis. Cases
for this study were self-reported Caucasians drawn from four additional Pfizer FM clinical
trial cohorts, recruited from North America (three studies) and Europe (one study). Controls
were drawn from healthy subjects from two Genetic Association Information Network
(GAIN) studies: one of psoriasis, recruited in the United States (8); and one of Major
Depressive Disorder (MDD), from the Netherlands (9). All genotyping was performed on
the genome-wide Perlegen 600K platform by Perlegen Sciences. Samples were removed due
to duplication, call rate <90%, or evidence of being an outlier with respect to ethnicity or
genotype heterozygosity rates. Filters for low quality SNPs were also applied: call rate
<95%; minor allele frequency <2% in any cohort; differential missingness p<10−5; Hardy-
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Weinberg equilibrium p<10−5; discordance with HapMap minor allele frequencies >33%.
Only SNPs (n=543) from the selected replication genes were used for association analysis in
this step. The final cleaned dataset included 1004 FM cases and 3725 controls, with an
overall genotyping rate of 99.5%.
Association Analyses
The case/control analysis was performed using logistic regression as implemented in
PLINK. Case status was considered as a binary dependent variable, with the number of
minor alleles as the independent variable in a test of an additive inheritance model. Subject
age was introduced as a covariate term in the regression model. Odds ratios (OR) with 95%
confidence intervals (95% CI) were calculated in order to describe the effect of the minor
allele on disease risk. As a simple Bonferroni correction is overly conservative, we used
spectral decomposition (10) to estimate the number of effectively independent SNPs tested
by the Pain Research Panel after accounting for the LD between neighboring SNPs, in order
to generate a p-value threshold to retain an experiment-wide α=0.05.
The number of SNPs to carry forward into the replication step is an important issue. One
common approach is to consider some arbitrary p-value cut-off. However, p-value
distribution for associated SNPs depends on the sample size, thus different cut-off values
have to be used for studies with different sample sizes. In addition, p-values do not directly
reflect the magnitude of an association effect. A different approach for choosing the number
of follow-up SNPs is to specify a minimum effect size of interest for true associations. Then,
given the sample size of the original study, a number of SNPs with the smallest p-values can
be determined to carry forward into the replication study. That number is calculated based
on a desired probability for these SNPs to contain one or at least one of several true
associations. To this end, the method of Kuo and Zaykin (11) was used to quantify the
number of rank-ordered SNPs revealed in our initial case/control study needed to have 80%
probability to detect a single true association from among these top results, given an average
risk allele frequency of 0.2 and a minimum detectable relative risk (RR) of 1.5.
Eleven genes from the initial case/control association test were tested in the second
replication cohort (Table 1). Logistic regression associated fibromyalgia case status with all
Perlegen-genotyped SNPs in each gene locus surrounding the observed association from the
discovery analysis.
Due to the limited overlap between SNPs genotyped by the Pain Research Panel and the
GAIN Perlegen platform, we used genotypes from the HapMap reference population to
impute additional SNPs at the replication gene loci. A set of HapMap SNP genotypes (Phase
3, release 1, build 36) filtered to include only SNPs with MAF >0.01 and genotyping rate
>0.95 was retrieved from the HapMap website in PLINK.ped/.map format. Chi-square
statistical tests using the “–proxy-assoc” command in PLINK assessed association between
imputed SNPs in the clinical trial cohort and fibromyalgia status. Results were regarded as
reliable only if the imputation algorithm had sufficient information to make a valid call; i.e.,
if the information content metric INFO> 0.80. The Pain Panel datasets were not imputed.
RESULTS
Evaluation of potential bias
The overall genotyping rate in the final dataset for the primary case/control study using the
Pain Research Panel was 99.8%, indicating a very low probability that differential
missingness rates in cases and controls might influence group allele frequencies. All of the
subjects in this study were Caucasian by self-report and by genetic clustering (see
Supplemental Figure 1), but the potential remains for bias due to subtle differences in ethnic
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makeup between case and control populations. Examination of the distribution of test
statistics, by Q-Q plot (Fig. 1) and by the genomic inflation factor statistic lambda,
suggested no systematic deviation from their expected distribution under the null that would
indicate population stratification. The quality control metrics of all SNPs with p-values
<0.01, including HWE p-values and missingness rates, showed no indication that these
associations are due to technical errors in sample quality or genotype calling accuracy
(Table 1).
Primary case/control associations
Results for the regression test contrasting FM cases against the control sample are plotted in
Fig. 2. The threshold for significance, adjusted for the number of SNPs tested and linkage
disequilibrium between them, was set to p<2.8×10−5. We observed two significant SNPs.
SNP rs4906902 is in the promoter region of the GABA-A β receptor gene, GABRB3, with
the minor allele of this SNP (−897 T>C) displaying a protective effect against FM in our
cohort (p=3.65×10−6, OR=0.46, 95% CI 0.33–0.64). This SNP is situated in a highly
evolutionarily conserved region (see USCS Human Genome Browser at
http://genome.ucsc.edu/), and the variant alters the binding sequence of the transcription
factor N-Oct-3, putatively leading to reduced expression of GABRB3. Mice with a deletion
of Gabrb3 display thermal hyperalgesia, tactile allodynia, and attenuated analgesic responses
to GABA receptor agonists (12).
The second significant association was observed at the SNP rs8192619, in the TAAR1 (trace
amine-associated receptor 1) gene that results in a synonymous amino acid substitution
(Cys265Cys) in the single exon of the TAAR1 locus (p=1.11×10−5, OR=3.8, 95% CI 2.1–
6.8). Although this SNP was not assessed in the replication study, a number of nearby
genotyped and imputed SNPs showed strong association effects in the replication cohort,
suggesting that rs8192619 tags a haplotype associated with increased risk in both cohorts,
confirming our initial finding. The TAAR family of receptors binds a range of biogenic
amines comprising <1% of endogenous amines in most brain areas with generally
uncharacterized effects, although it has been proposed that they modulate dopaminergic
activity (13).
An alternative method for determining significance identifies SNPs that are elevated above
the chance “expected” line of the p-values in a Q-Q plot. Fig. 1 shows that while the
distribution of tested SNPs followed the expected line, three SNPs clearly deviated from it,
also including rs7911, in the 3’-untranslated region of the GBP1 guanylate binding protein 1
(p=1.06×10−4, OR=1.7, 95% CI 1.3–2.1), with the minor C allele (T918C) increasing risk
for FM. This gene is induced by interferon and other cytokines, and may contribute to
inflammatory diseases including psoriasis (14) and inflammatory bowel disease (IBD) (15).
No pain phenotypes arising from genetic variation in GBP1 have been previously observed.
Next, to identify SNPs to carry forward into the replication step we used the method of Kuo
and Zaykin (11). This method estimates the number of top SNPs to contain a true
association with a desired probability. We calculated that a true association with RR≥1.5
would be found among the top 25 SNPs, ranked by p-value, with 80% probability. These 25
SNPs corresponded to a threshold of p≤0.01 in our results, implicating 8 additional genes to
test in the replication experiment (after removing 5 SNPs that failed quality checks or were
ancestry-informative markers): NPY1R (neuropeptide Y receptor 1); GBP2 (although this
may simply reflect the signal from the nearby GBP1, due to linkage disequilibrium); CNR1
(cannabinoid receptor 1); GRIA4 (glutamate receptor, ionotrophic, AMPA 4); GAL
(galanin); RGS4 (regulator of G-protein signaling 4); GPX4 (glutathione peroxidase 4
[phospholipid hydroperoxidase]); and ESR2 (estrogen receptor 2 [beta]).
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The 11 genes corresponding to the top 25 ranked SNPs were then examined in the second
cohort, using densely situated genotypes from the Perlegen platform, with the exception of
GPX4 for which data was not available. Where Perlegen data were missing, we attempted to
impute SNPs based on HapMap haplotype frequencies. P-values from the two cohorts were
compared, taking into consideration direction of effect and strand orientation, to confirm
previously observed associations. The distribution of the p-values from the genes deviated
substantially from that expected under the null hypothesis, which is likely explained by non-
random selection of the gene loci and enrichment for loci contributing to FM (Supp. Fig. 3).
The strongest association in the original case/control study was SNP rs4906902, in the
GABRB3 gene (Fig. 3A). This SNP was not significantly associated with FM status in the
replication cohort (p=0.49). No other nearby SNPs demonstrated an association signal in this
cohort.
The second-ranked SNP, rs8192619 in the TAAR1 gene (Fig. 3B), was not genotyped in the
replication set, and could not be imputed since it was not included in the HapMap dataset.
However, a number of flanking SNPs were strongly associated with fibromyalgia in the
replication cohort, including rs4129256 (p=2.20×10−4, OR=1.3 or with missing values
imputed p=8.63×10−5, OR=1.3), located in an intron of the neighboring TAAR2 gene, and
the imputed SNP rs2745428 (p=1.74×10−4, OR=1.3, INFO=0.95).
The strongest associated SNP in the GBP1 gene, rs7911, was not genotyped in the
replication cohort and was only poorly imputed, with a p-value that barely exceeded
significance (uncorrected one-tailed test, p=0.03, OR=1.1, INFO=0.78, Fig. 3C). A second
region of suggestive association in the GBP1 gene was located about 55kb downstream,
with p-values between 1.3–3.5×10−3. This region showed no similar evidence for
association in the replication cohort.
Several other genes showed evidence for association only in the replication cohort at levels
greater than expected by chance. Genes containing SNPs that exceeded a corrected p-value
threshold of p≤1.63×10−4 (for 306 independent SNPs tested in the replication study)
included RGS4, CNR1, and GRIA4. The other genes examined in the replication step,
including GBP2, NPY1R, GAL, and ESR2, did not confirm the original SNP associations,
and showed weak to no association at other SNPs.
Located in an intron of the RGS4 (regulator of G-protein signaling 4, Fig. 3D) gene, the
A158G SNP was suggestively associated with FM (rs10799897, p=2.4×10−3, OR=1.47,
95% CI=1.1–1.9), but was neither genotyped nor imputed in the replication cohort. Two
other SNPs showing association in the replication cohort (rs2842003, p=9.6×10−4, OR=1.2;
SNP rs2805050, imputed p=6.0×10−5, OR=3.4, INFO=1.18) likely represent distinct risk
markers rather than replication, since they are not in LD with rs10799897.
The CB-1 cannabinoid receptor gene CNR1 (Fig. 3E) had one SNP that qualified for the
replication study, an intronic A>C substitution (rs6454674, p=7.2×10−3, OR=0.7, 95% CI
0.5–0.9). This SNP was not genotyped in the replication cohort and was not found in the
HapMap dataset used for imputation. However, several tightly linked promoter region SNPs
(about 25 kb upstream) showed strong associations with FM, suggesting that a haplotype
near the original SNP harbors the true risk polymorphism. These SNPs included a G>A
polymorphism (rs1078602, p=3.7×10−4, OR=0.8) and an imputed A>G substitution
(rs10485171, p=1.6×10−4, OR=0.8, INFO=0.90), although the functional consequences of
these variants are not known.
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The lowest p-value SNP in the GRIA4 gene (Fig. 3F), which codes for the AMPA
ionotropic glutamate receptor 4 subunit, was a protective intronic T4086G change
(rs642544, p=9.3×10−3, OR=0.72, 95% CI=0.57–0.92). This SNP was not genotyped in the
replication dataset, and was only poorly imputed (p=0.14). However, a group of genotyped
SNPs in LD with rs643544 (D’=1.0, r2=0.67) but with lower MAF showed even stronger
evidence for association, including rs17104711 (p=2.4×10−3, OR=1.3). It should be noted
that the direction of effect for the minor allele for these SNPs in the replication cohort is
reversed compared to rs642544. Another region upstream from the GRIA4 locus not in LD
with the original associated SNP was also observed to show strong evidence for association
with FM, including the genotyped SNP rs2510177 (p=1.1×10−3, OR=1.3), and two imputed
SNPs in complete LD with each other, rs10895837 and rs10502058 (p=9.2×10−5, OR=1.3,
INFO=0.98). Given the complex LD structure of this gene and the lack of overlapping SNPs
in both cohorts, it is difficult to decode an association pattern and contribution of each SNP
without further dense genotyping of this locus; however, it seems that genetic variants of
GRIA4 contribute to FM.
Multiple SNPs in each gene were tested in the replication sample. Therefore, the largest
odds ratio estimates obtained for each gene are not unbiased. A method by Ghosh et al. (16)
was used to obtain bias reduced estimates of odds ratios. The corrected odds ratio values
were 2.62 (rs2805050, RGS4); 0.95 (rs10485171, CNR1); 1.12 (rs4129256, TAAR1) and
1.11 (rs10895837, GRIA4). Corrected odds ratios for other genes did not significantly differ
from one.
Previously associated FM genes
Several genes have been investigated for polymorphisms that increase risk for FM and
chronic widespread pain, with a number of implicated genetic variants. The Pain Research
Panel assesses many of these genes, often with more extensive coverage than the original
candidate gene studies. For the majority of these candidates, no evidence of association with
FM was detected in our cohort.
Serotonergic genes have been extensively investigated for risk variants for FM. The long
allele of a 44-base pair insertion/deletion in the promoter region of the 5-HTT transporter
gene SLC6A4 has been associated with FM in German (17) as well as Israeli cohorts, but
not in Turkish subjects (18), nor was it associated with FM pain severity in a recent report of
Canadian patients (19). Although the Pain Research Panel does not include this variant, no
SNPs from this gene exceeded a nominal significance threshold of p<0.01. FM and pain
severity have also been associated with the silent T102C (rs6313) SNP of the serotonin 2A
receptor gene HTR2A (20). The Pain Research Panel SNP rs4941573 is a useful tag for
rs6313 (tight LD r2=1.0), and no association was observed for this marker in our cohort
(p=0.86).
Genes relevant to catecholaminergic neurotransmission have also been examined in FM,
including the dopamine transporter gene SLC6A3 (21) and the dopamine D4 receptor DRD4
(22); or with painful symptoms in the D3 dopamine receptor DRD3 (23), and the β2- and
α1A-adrenergic receptor genes ADRB2 and ADRA1A (24). We observed no evidence for
association with these genes in our cohort, although no DRD4 SNPs passed genotype quality
inspection. Other studies have investigated the role of MAO and COMT, which metabolize
catecholamines and influence the bioavailability of these neurotransmitters. Although
variants of the two MAO genes MAOA and MAOB have not been implicated in FM risk
(25, 26), the low-activity variant of the COMT Val158Met (rs4680) polymorphism occurs
more often in FM patients in some studies (27–29), but not in others (30, 31). In our FM
cohort, we observed no association with a tag SNP proxy (rs4633) for the Val158Met
polymorphism (p=0.54), nor the functional haplotypes of COMT (32).
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A large scale candidate gene approach was used to evaluate over 350 genes known to be
involved in nociception, inflammation, and affect. While not an exhaustive survey of all
pathways potentially involved in the pathophysiology of FM, the study provided a
comprehensive and in-depth evaluation of the majority of genes currently known to
influence persistent pain conditions. Three unsuspected genes, GABRB3, TAAR1, and
GBP1, harbored SNPs that differed in frequency between FM patients and healthy controls;
TAAR1 displayed evidence for association in a second cohort. The available meager
evidence suggests that receptors for trace amines might influence the development of
chronic pain by modulating activity of dopaminergic receptors (33). TAAR-induced
alterations in dopamine bioavailability and function may increase pain sensitivity, a
hallmark of FM (34). This receptor presents an interesting target for the development of
novel TAAR-selective compounds with analgesic properties (35).
Three additional genes—RGS4, CNR1, and GRIA4—were suggestively implicated in two
different cohorts, indicating convergent evidence for their involvement in FM susceptibility.
Like TAAR1, two of these genes play important roles in the modulation of analgesic
pathways.
RGS4, expressed in CNS regions such as the locus coeruleus (LC), the bed nuclei of the
stria terminalis, and the dorsal horn of the spinal cord (36), negatively regulates G protein
signaling and may therefore play a modulatory role in descending inhibition of pain
perception. Within the noradrenergic nucleus of the LC, overexpression of RGS4 down-
regulates μ-opioid receptor function (37), and in the spinal cord RGS4 is upregulated up to
230% in a rat model of neuropathic pain, resulting in a substantial attenuation of morphine
analgesia (38).
The analgesic properties of the CB-1 cannabinoid receptor encoded by CNR1 have been
well-documented, and the cannabinoid agonist nabilone has demonstrated improvements in
pain and life quality in patients with FM (39). However, the question remains whether
endocannabinoid activity contributes to the etiology of FM. Variants within the CNR1 locus
have been associated with other painful chronic conditions, such as irritable bowel syndrome
(IBS) (40), migraine (41) and post-traumatic stress disorder (PTSD) (42). FM patients have
an increase in circulating anandamide, an endocannabinoid (43), which may be a marker of
a “clinical endocannabinoid deficiency,” hypothesized to underlie idiopathic pain conditions
such as FM (44). It also raises the possibility of the existence of a specific clinical cluster of
FM patients with deficiency in the cannabinoid system that could be identified by a genetic
test and would benefit from drugs like nabilone.
In contrast to the effects of TAAR1, RGS4, and CNR1 genetic variants on analgesic
mechanisms, the association of GRIA4 with FM might be due to production of central
sensitization, a hallmark of FM and related conditions (45). GRIA4 encodes the AMPA-
sensitive, ionotropic glutamate receptor subunit GluR4, which mediates fast excitatory
transmission of nociceptive signals in the CNS. Little is known about the specific
contribution of this receptor subunit to the development of hypersensitivity, but AMPA
receptors in the brain and spinal cord are integral to synaptic plasticity and the development
of persistent pain (46). AMPA receptors in analgesia-related brain regions, such as the
rostral ventromedial medulla (RVM), are also involved in descending modulation of pain
perception (47). Spinal AMPA receptors have also been implicated in the production of
visceral hyperalgesia (48). Collectively, these observations suggest that alterations in AMPA
receptors are likely to contribute to the complex signs, symptoms, and comorbidities
associated with FM.
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FM patients have been classified by patterns of symptom presentation (49, 50); it may be
useful to incorporate genotypic information into such clustering exercises to account for
inherited susceptibility to certain intermediate phenotypes, and to associate specific risk
factors with clinical outcomes. By implicating a set of genes known to influence nociceptive
and analgesic pathways, this study provides evidence for multiple biological mechanisms
underlying the pathophysiology of FM, and suggests novel avenues of investigation into the
roles that these systems play in the development of persistent pain conditions. Dysfunction
within descending inhibitory circuitry, originating from deficiencies in GABAergic,
aminergic, or cannabinoid signaling, may lead to an insufficient analgesic response that
predisposes certain individuals to chronic pain following trauma or stress. Others might be
predisposed to central sensitization due to hyperexcitability of glutamatergic receptors or an
increased response to inflammatory cytokines. Future research should consider the
heterogeneity of FM and the diversity of instigators of persistent pain, which will increase
the power of genetic studies to identify risk determinants, and will improve the prospects for
an individualized approach to treating FM and other chronic pain diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Q-Q plot of FM case/control test. The observed (−log10) p-value distribution (blue dots) is
plotted against the expected distribution under the null hypothesis (red line). Systematic
elevation from chance over the range of expected values indicates underlying population
structure that can bias associations. The genomic inflation factor statistic lambda suggested
no such inflation (λ = 0.91).
Smith et al. Page 13














Manhattan plot of FM case/control test. The observed (−log10) p-values of all tested SNPs
are plotted against their chromosomal position. The red line shows the significance threshold
to retain an experiment-wide α = 0.05, adjusting for the estimated number of independent
SNPs. The blue line represents a nominal significance value of p = 0.01, the threshold
corresponding to the top 25 rank-ordered SNPs revealed in our initial case/control study
needed to have 80% probability to detect a single true association from among these top
results considering an average risk allele frequency of 0.2 and an estimated relative risk RR
= 1.5. This threshold was then used to select genes to carry forward to the replication step.
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Annotated results in genomic context for top associated genes in the discovery step (A, B,
C) and additional replication supported genes (D, E, F). In the upper section of each figure,
transformed −log10(p-values) for each SNP are graphed on the y-axis against their genomic
location (scale in Mb) on the x-axis. Association results from the discovery study are
indicated by circles; results from genotyped SNPs in the replication study are indicated by
squares, and well-imputed SNPs in this study are indicated by triangles. The lower section
of each figure shows gene loci aligned to the same coordinates. The top associated SNP
from the discovery phase is labeled and indicated by a purple diamond; the color of the other
SNP symbols indicates LD with this SNP (information from the HapMap CEU population),
in r2 values as indicated by the legend. A. GABRB3, B. TAAR1, C. GBP1, D. RGS4, E.
CNR1, F. GRIA4.
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